Consenus conference on high-dose therapy with hematopoietic stem cell trnasplantation in diffuse large-cell lymphoma. Type of cells, optimal mobilization of stem cells - Positive and negative selection

Annals of Oncology

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Kessinger, A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Blood cell transplant; Marrow transplant

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR;

AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; GROWTH STIMULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; ALLOTRANSPLANTATION; APHERESIS; BONE MARROW TRANSPLANTATION; CYTOLOGY; DRUG EFFECT; FETUS BLOOD; GENETIC SELECTION; HEMATOPOIETIC STEM CELL; METHODOLOGY; MULTIMODALITY CANCER THERAPY; STEM CELL MOBILIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FETAL BLOOD; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; SELECTION (GENETICS); TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031943203     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_1.S23     Document Type: Review

References (86)

1. Mc Farland W, Granville NB, Damesheck W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood 1959; 14: 503-21.
2. Appelbaum FR, Herzig GP. Ziegler JL et al. Successful engraftment of cryopreserved autologous hone marrow in patients with malignant lymphoma. Blood 1978; 52: 85-95.
3. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or highgrade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-8.
4. Hill RS, Mazza P, Amos D et al. Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 1989; 4: 69-74.
5. Nemunaitis F, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous hone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-8.
6. Linch DC, Scarffe H, Procter S et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-11.
7. Passweg JR, Rowlings PA, Armitage JO et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. In Cecka JM. Terasaki PI (eds): Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory 1995; 117-27.
8. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplants in Europe: Activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 137-48.
9. Johnson HE, Hansen PB. Plesner T et al. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant 1992; 10: 229 34.
10. Hansen PB, Knudsen H, Gaarsdal E et al. Short-term in vivo priming of bone marrow hematopoiesis with rhG-CSF. rhGM-CSF or rhlL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability. Bone Marrow Transplant 1995; 16: 373-9.
11. Janssen WE, Smilee RC, Elfenbein GJ. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematother 1995; 4: 139-40.
12. Bishop MR, Anderson JR, Jackson JD et al. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-6.
13. Dicke KA, Hood DL, Arneson M et al. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol 1997; 25: 34-8.
14. Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997; 90: 36-42.
15. Goldman JM, Johnson SA, Islam A et al. Hematological reconstitution after autografting for chronic granulocytic leukaemia in transformation: The influence of previous splenectomy. Br J Haematol 1980; 45: 223-31.
16. Hershko C, Ho WG, Gale RP et al. Cure of aplastic anaemia in paroxysmal nocturnal hemoglobinuria by marrow transfusion from identical twin: Failure of peripheral leucocyte transfusion to correct marrow aplasia. Lancet 1979; 1: 945-47.
17. Abrams RA. Glaubiger D, Appelbaum FR et al. Result of attempted hematopoietic reconstitution using isologous peripheral blood mononuclear cells: A case report. Blood 1980; 56: 516-20.
18. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells collected in very early remission from acute nonlymphoblastic leukaemia produce prompt but incomplete hemopoietic reconstitution after high-dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739-46.
19. Bell AJ, Figes A, Oscier DG et al. Peripheral blood stem cell autografting. Lancet 1986; 1: 1027.
20. Korbling M, Dorken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-32.
21. Tilly H, Bastit D, Lucet J-C et al. Haemopoietic reconstitution after autologous peripheral blood stem cell transplantation in acute leukaemia. Lancet 1986; 1: 154-5.
22. Kessinger A, Armitage JO, Landmark JD et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14: 192-6.
23. Reiffers J, Bernard P, David B et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312-5.
24. Castaigne S, Calvo F, Douay L et al. Successful haematopoietic reconstitution using autologous peripheral blood mononucleated cells in a patient with acute promyelocytic leukaemia. Fr J Haematol 1986; 62: 209-11.
25. Kessinger A, Vose JM, Berman PJ et al. High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: An alternative to bone marrow purging. Exp Hematol 1991; 12: 1013-16.
26. Korbling M, Holle R, Haas R et al. Autologous blood stem-cell transplantalion in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 1990; 8: 978-85.
27. Kessinger A, Berman PJ, Vose JM et al. High-dose cyclophosphamide, carmustine and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322-5.
28. Williams SF, Bitran JD, Richards JM et al. Peripheral blood-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: An alternative approach. Bone Marrow Transplant 1990; 5: 129-33.
29. Kessinger A, Armitage JO, Smith DM et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260 5.
30. Ellis ED, Williams SF, Moormeier JA et al. A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplant 1990;6:439-42.
31. Richman CM,Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-9.
32. Stiff PJ, Murgo AJ, Wittes RE et al. Quantification of the peripheral blood colony forming unit-culture rise following chemotherapy. Could leukocytaphercses replace bone marrow for autologous transplantation? Transfusion 1983; 23: 500-3.
33. To LB, Haylock DN, Kimber RJ et al. High levels of circulating haemopoietic stem cells in very early remission from acute nonlymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1994; 58: 300-410.
34. To LB, Haylock DN. Thorp D et al. The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia. Bone Marrow Transplant 1989; 4: 41-7.
35. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-7.
36. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-7.
37. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239-48.
38. Demirer T, Buckner DC, Lilleby K et al. Failure of a single cycle of high-dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. Cancer 1994; 74: 715-21.
39. Duhrsen U, Villeval JL, Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-81.
40. Socinski MA, Cannistra S, Elias A et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-8.
41. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-63.
42. Hartmann O, LeCorroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-7.
43. VanBesien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299-307.
44. Shepherd JD, Barnett MJ, Conners JM et al. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12: 591-6.
45. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690-5.
46. Pavletic ZS, Bishop MR, Tarantolo SR et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608-16.
47. Majolino I,. Saglio F, Scime R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555-60.
48. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-800.
49. Korbling M, Przepiorka D, Huh Y et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-65.
50. Anderlini P, Korbling M, Dale D et al. Allogeneic blood stem cell transplantation: Considerations for donors. Blood 1997; 90: 903 8.
51. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation form related and unrelated donors. N Eng J Med 1997; 337: 373-81.
52. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 1992; 79: 1193-200.
53. Haas R, Hohaus S, Egerer G et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 1992; 9: 459-65.
54. Schwartzberg LS, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-27.
55. Pettengell R, Morgenstern GR, Woll PJ et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-7.
56. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82.
57. Winter JN, Lazarus HM, Rademaker A et al. Phase I- II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-86.
58. Bishop MR, Jackson JD, O'Kane-Murphy B et al. Phase 1 trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. J Clin Oncol 1966; 14: 2521-6.
59. Roman-Ufer S, Bitran JD, Garrison L et al. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells. Exp Hematol 1996; 24: 823-8.
60. Geissler K, Peschel C, Niederwieser D et al. Potentiation of granulocyte colony-stimulating factor - induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996; 87: 2732-9.
61. Pettengell R, Woll PJ, Chang J et al. Effects of erythropoietin on mobilisation of haemopoietic progenitor cells. Bone Marrow Transplant 1994; 14: 125 30.
62. Kessinger A, Bishop MR, Jackson JD et al. Erythropoietin for mobilization of circulating progenitor cells in patients with previously-treated relapsed malignancies. Exp Hematol 1995; 23: 609-12.
63. Kessinger A, Bishop M, Schmit-Pokorny K et al. Granulocytemacrophage colony stimulating factor and erythropoietin, alone or in combination for blood progenitor cell mobilization. Blood 1996; 88 (Suppl 1): 400a.
64. Olivieri A, Offidani M, Cantori I et al. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 1995; 16: 765-70.
65. Weaver A, Ryder D, Crowther D et al. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996; 88: 3323-8.
66. Moskowitz CH, Stiff P, Gordon MS et al. Recomibinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients results of a phase I - II trial. Blood 1997; 89: 3136-47.
67. Brugger W. Bross JK, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
68. Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996; 87: 1625-34.
69. Vora AJ, Toh CH, Peel J et al. Use of granulocyte colonystimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994; 86: 180-2.
70. Sharp JG, Chan W, Wu G et al. Comparison of culture versus molecular detection of lymphoma in the context of a randomized prospective trial of blood versus marrow for reconstitution after high-dose therapy: An interim analysis. In Dicke KA. Keating A (eds): Autologous Bone Marrow Transplantation. Proceedings of the Eighth International Symposium. Charlottesville, VA: Carden Jennings (in press).
71. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787 94.
72. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-55.
73. Bensinger WI, Clift RA, Anasetti C et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells 1996; 14: 90 105.
74. Roberts AW, Foote S, Alexander WS et al. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 1997; 89: 2736-44.
75. Sharp JG, Mann S, Murphy B et al. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review, J Hematother 1995; 4: 141-8.
76. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in hone marrow. Blood 1994; 83: 3800-7.
77. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-9.
78. Vaughan WP, Weisenburger DD, Sanger W et al. Early leukemic recurrence of non-Hodgkin lymphoma after high-dose anti-neoplastic therapy with autologous marrow rescue. Bone Marrow Transplant 1997; 19: 373-8.
79. Rossetti F, Deeg HJ, Hackman RC, Early pulmonary recurrence of non-Hodgkin's lymphoma after autologous marrow transplantation: Evidence for reinfusion of lymphoma cells. Bone Marrow Transplant 1995; 15: 429 32.
80. Vose JM, Sharp JG, Chan W et al. High-dose chemotherapy and autotransplant for non-Hodgkin's lymphoma: Randomized trial of peripheral blood versus bone marrow and evaluation of minimal residual disease. Proc Am Assoc Clin Oncol 1997; 16: 90a.
81. Brenner MK, Rill DR, Moen RC Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-6.
82. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-76.
83. Weisdorf DJ, Haake R, Miller WJ et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: Clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant 1991; 8: 135-42.
84. Peterson FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-47.
85. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-41.
86. Williams CD, Goldstone AH, Pearce R et al. Purging of bone marrow in autologous bone marrow transplantation for nonHodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454-64.